Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Published:2019-01 Issue:1-2 Volume:176 Page:334-347.e12
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Wang Jun,Sanmamed Miguel F.,Datar Ila,Su Tina Tianjiao,Ji Lan,Sun Jingwei,Chen Ling,Chen Yusheng,Zhu Gefeng,Yin Weiwei,Zheng Linghua,Zhou Ting,Badri Ti,Yao Sheng,Zhu Shu,Boto Agedi,Sznol Mario,Melero Ignacio,Vignali Dario A.A.,Schalper Kurt,Chen Lieping

Funder

NIH

Boehringer Ingelheim

United Technologies Corporation

Instituto de Salud Carlos III, Fondo de Investigación Sanitaria

NCI Comprehensive Cancer Center Support CORE

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference62 articles.

1. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation;Anderson;Immunity,2016

2. LAG3 (CD223) as a cancer immunotherapy target;Andrews;Immunol. Rev.,2017

3. Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production;Annunziato;FASEB J.,1996

4. Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells;Annunziato;Eur. J. Immunol.,1997

5. Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?;Ascierto;J. Transl. Med.,2017

Cited by 607 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus;Journal of Translational Autoimmunity;2024-12

2. Screening, expression and anti-tumor functional identification of anti-LAG-3 nanobodies;Protein Expression and Purification;2024-10

3. Comparative analysis of transcriptomic and proteomic expression between two non-small cell lung cancer subtypes;2024-09-10

4. Immune checkpoint inhibitors in infectious disease;Immunological Reviews;2024-09-09

5. Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3